Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.
USD 29.95
Information on this company is supplied by EMIS which is part of Euromoney Institutional Investor plc, one of Europe's largest publishers and a constituent of the FTSE 250 index.

Contact Information

Legal Address
Kalbe Building,Jl. Letjend. Suprapto Kav. 4,P.O. Box 3106 Jak
Jakarta; Jakarta; Map
Postal Code: 10510
Tel: +62-21-4287-
Fax: +62-21-4287-
Email: @kalbe.co.id
Website: http://www.kalbe.co.id

Full name: Pt Kalbe Farma Tbk

Status: Listed
Legal Form: Public Limited Company
Operational Status: Operational
EMISid: 1611156
ISIN: ID1000096803
Incorporation Date: 1966

Main Activities

Main Activities: Pharmaceutical and Medicine Manufacturing

Main Products

Pharmaceutical products

Company Description

PT. Kalbe Farma Tbk. (KLBF) operates as a pharmaceuticals manufacturer. KLBF retains strategic alliances through its licensing agreements with some of the world pharmaceutical companies, including Fujisawa Pharmaceutical Co., Ltd., Bristol Myers Squibb, Baxter and Pharmacia Upjohn. KLBF was listed on Indonesia Stock Exchange in 1991 under the Main Board. The company was founded in 1966, with the head office located in Jakarta and factory in Bekasi, West Java.

More

Basic Information

Total Employees:
()
Outstanding Shares:
: ()
Financial Auditors:
()

EMIS Benchmark Score

View all parameters in Benchmark Score

Quote Chart

Quote Summary

Last Price 1,505.00
Volume 11,086,200
Turnover 16,878,739,500
Index    Jakarta Composite Index
Market Bursa Efek Indonesia
Ticker KLBF
Market Cap Market Cap 70,547,058,610
52 Week High 1,815.00
52 Week Low 1,265.00
Price to Earnings (P/E) 35
Earnings per Share (EPS) 42
Dividend Yield 19 (Desember 31, 2015)
Bookvalue 13,300,712,968
Enterprise Value 68,227,349,663
Quote updated on January 16, 2017
Note: data in IDR Thousands.

Key Executives

President

Ownership Details

Pt Diptanala Bahana - ORDINARY SHARES
More

Key Stats

Select Items to chart them. 2016 Q3C
Net sales revenue
Total operating revenue
Operating profit (EBIT)
EBITDA
Net Profit (Loss) for the Period
Total assets 14,688,501,466
Total equity
Operating Profit (EBIT) Margin
Return on Sales (ROS)
Return on Equity (ROE)
Debt to Equity
Quick Ratio
Cash Ratio
Note: units in Thousands. Statement: Non-Audited, Consolidated
Source: World's Vest Base, EMIS Company Database.

Financials

Competitors - Indonesia

IDR | USD | EUR

EMIS DealWatch Deals

DealMonitor Deal Intents

for 29.95 USD
Payment methods include:
USD 29.95
Most recent financial data: 2015
Payment methods include:
The full PDF report for this company will be available to download immediately after purchase. The report will contain:
Company Tear Sheet
Contact Information
NAICS Industry Classification
Business description
Basic Information
Share Price information
Key Executives
Ownership Details
Subsidiaries and Affiliates
Key Financial Highlights
Financial Performance Charts
Latest M&A and ECM Deals
Top Competitors
Financial Statements
Annual Statements
Ratios
EMIS Credit Analytics
EMIS Benchmark Score

- or -

EMIS company profiles are part of a larger information service that combines company, industry and country data and analysis for over 120 emerging markets on a unique information platform.

If you need broad and deep coverage of one or many countries, you may be interested in subscribing. Request a demonstration of our full service and one of our account managers will be in touch.

Register Your Interest